Odonate Therapeutics (ODT) Downgraded by ValuEngine

ValuEngine cut shares of Odonate Therapeutics (NASDAQ:ODT) from a buy rating to a hold rating in a research report released on Thursday, ValuEngine reports.

ODT has been the subject of several other reports. Zacks Investment Research upgraded Odonate Therapeutics from a sell rating to a hold rating in a research report on Tuesday, December 25th. Cowen reiterated a buy rating on shares of Odonate Therapeutics in a research report on Friday, February 22nd.

Shares of ODT opened at $21.40 on Thursday. Odonate Therapeutics has a 52-week low of $11.54 and a 52-week high of $28.57. The company has a market capitalization of $572.51 million, a P/E ratio of -5.88 and a beta of 1.10.

Odonate Therapeutics (NASDAQ:ODT) last issued its quarterly earnings data on Friday, February 22nd. The company reported ($1.17) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.07) by ($0.10). Research analysts anticipate that Odonate Therapeutics will post -4.56 earnings per share for the current fiscal year.

In other news, Director Jeff L. Vacirca purchased 3,000 shares of Odonate Therapeutics stock in a transaction on Monday, March 4th. The stock was purchased at an average price of $17.00 per share, with a total value of $51,000.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Kevin C. Tang purchased 140,000 shares of Odonate Therapeutics stock in a transaction on Friday, March 8th. The shares were purchased at an average cost of $18.26 per share, with a total value of $2,556,400.00. The disclosure for this purchase can be found here. Corporate insiders own 49.00% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp raised its stake in shares of Odonate Therapeutics by 3.6% during the 3rd quarter. Bank of New York Mellon Corp now owns 84,341 shares of the company’s stock worth $1,637,000 after purchasing an additional 2,915 shares in the last quarter. BlackRock Inc. raised its stake in shares of Odonate Therapeutics by 1.4% during the 3rd quarter. BlackRock Inc. now owns 338,825 shares of the company’s stock worth $6,576,000 after purchasing an additional 4,566 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in shares of Odonate Therapeutics by 222.8% during the 3rd quarter. Tower Research Capital LLC TRC now owns 5,288 shares of the company’s stock worth $102,000 after purchasing an additional 3,650 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Odonate Therapeutics by 18.5% during the 3rd quarter. Vanguard Group Inc. now owns 316,733 shares of the company’s stock worth $6,148,000 after purchasing an additional 49,528 shares in the last quarter. Finally, Federated Investors Inc. PA bought a new stake in shares of Odonate Therapeutics during the 3rd quarter worth approximately $68,000. 94.02% of the stock is owned by hedge funds and other institutional investors.

Odonate Therapeutics Company Profile

Odonate Therapeutics, Inc, a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.

Further Reading: Market Capitalization and Individual Investors

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.